Actinium pharmaceuticals announces active presence at the bmt tandem meetings nyse_atnm

ORLANDO, Fla., Feb. Top 5 fast food restaurants 23, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. Food and restaurants near me (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation (ASBMT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Restaurants food near me The conference is being held on February 22 – 26, 2017 at the Gaylord Palms Convention Center in Orlando, Florida.

The BMT Tandem Meetings include an extensive scientific program that addresses state-of-the-art issues in bone marrow transplant. Restaurants near me fast food Meeting attendees include investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, administrators and allied health professionals seeking to benefit from its hematopoietic cell transplantation focused program. Find fast food restaurants The team from Actinium is comprised of clinical, medical, business development and marketing personnel and has a full agenda of activities related to advisory board meetings, a booth presence for Iomab-B and the SIERRA trial, as well as meetings with potential partners and collaborators.


Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, “Our lead drug candidate, Iomab-B, is being developed to prepare patients for a bone marrow transplant with the hopes of enabling an increased number of elderly patients with relapsed or refractory leukemia to obtain a transplant compared to current salvage chemotherapy conditioning. Best food restaurants near me Given our focus on transplant, the BMT Tandem meetings are a major event for us, which give us great insights into this exciting field while motivating us to all we can to improve outcomes for patients in need.”

Annually, the BMT Tandem Meetings are the largest gathering in North America of worldwide experts in blood and marrow transplant patient care, clinical investigation and laboratory research. New fast food restaurants Over 3,000 transplant physicians in over 500 transplant centers from >50 countries participate in the CIBMTR. Chain food restaurants The ASBMT has a membership of over 2,300 clinicians and researchers. Fast food restaurants in the area By combining our meetings, we expect over 3,200 participants at next year’s meetings representing more than 50 countries, with approximately 20% coming from outside the United States.

Iomab-B is Actinium’s lead product candidate that is currently being studied in a 150-patient, multicenter pivotal Phase 3 clinical trial in patients with relapsed or refractory acute myeloid leukemia who are age 55 and above. Nearby food restaurants Upon approval, Iomab-B is intended to prepare and condition patients for a bone marrow transplant, also referred to as a hematopoietic stem cell transplant, which is often considered the only potential cure for patients with certain blood-borne cancers and blood disorders. Food restaurants nearby Iomab-B targets cells that express CD45, a pan-leukocytic antigen widely expressed on white blood cells with the monoclonal antibody, BC8, labeled with the radioisotope, iodine-131. Fast food restaurants in this area By carrying iodine-131 directly to the bone marrow in a targeted manner, Actinium believes Iomab-B will avoid the side effects of radiation on most healthy tissues while effectively killing the patient’s cancer and marrow cells. Fast food chain restaurants In a Phase 2 clinical study in 68 patients with advanced AML or high-risk myelodysplastic syndrome (MDS) age 50 and older, Iomab-B produced complete remissions in 100% of patients and patients experienced transplant engraftment at day 28. Open food restaurants near me Iomab-B was developed at the Fred Hutchinson Cancer Research Center where it has been studied in almost 300 patients in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin’s disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). Fast food restaurants open Iomab-B has been granted Orphan Drug Designation for relapsed or refractory AML in patients 55 and above by the U.S. Food restaurants near my location Food and Drug Administration and the European Medicines Agency.

Actinium Pharmaceuticals, Inc. Food restaurants around me is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Most popular fast food restaurants Actinium’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Food chain restaurants The Company’s lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. Junk food restaurants A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Restaurants and food Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. Food near me restaurants The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. Fast food and restaurants The Company’s second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Restaurants american food Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. American food restaurants In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Worst fast food restaurants Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Fast food restaurants usa Actinium Pharmaceuticals is based in New York, NY. Restaurants and fast food To learn more about Actinium Pharmaceuticals, please visit www.actiniumpharma.com and to follow @ActiniumPharma on Twitter please visit, www.twitter.com/actiniumpharma.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Most fast food restaurants These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. Fast food restaurants in america The forward-looking statements may include statements regarding product development, product potential, or financial performance. Top fast food restaurants 2016 No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Fast food restaurants in my area Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

GlobeNewswire, a Nasdaq company, is one of the world’s largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Leave a Reply

Your email address will not be published. Required fields are marked *